Stories about: David Roberson

A calmer rodent is a better rodent for pain medication research

The global market for pain medications is huge — some estimates predict it will hit $41.6 billion by 2017. However, the costs of pain medicine development are huge, too; it takes roughly $900 million to bring a new analgesic compound to market. In part, this is because some 80 percent of compounds that look promising in preclinical animal studies (largely in rodents) fail in late-stage clinical trials.

David Roberson, MBA, a neuroscience graduate student in the F.M. Kirby Neurobiology Center at Boston Children’s Hospital, wants to make those preclinical studies better at predicting whether a new compound will work safely in people — by studying rodents at “home.”

Read Full Story | Leave a Comment